Quantcast

Latest Antidepressants Stories

2010-12-08 16:32:49

Ground-breaking research from Professor Douglas Kell, published in the journal Archives of Toxicology, has found that the majority of debilitating illnesses are in part caused by poorly-bound iron which causes the production of dangerous toxins that can react with the components of living systems. These toxins, called hydroxyl radicals, cause degenerative diseases of many kinds in different parts of the body. In order to protect the body from these dangerous varieties of poorly-bound iron, it...

2010-11-23 00:01:06

OLEPTROâ“ž¢ Data Presented at U.S. Psychiatric and Mental Health Congress OLEPTROâ“ž¢ Offers Physicians a Treatment Alternative for Patients with Major Depressive Disorder Princeton, NJ (Vocus) November 22, 2010 This week at the 2010 U.S. Psychiatric and Mental Health Congress in Orlando, FL, Angelini Labopharm presented two analyses from the pivotal clinical trial for OLEPTROâ“ž¢ (trazodone...

2010-11-19 00:00:42

Media Advisory ** Interview Opportunity Princeton, NJ (Vocus) November 18, 2010 Major depressive disorder (MDD) is a common mental illness that affects more than 14 million American adults. It can seriously impact every area of a person's life and, if left untreated, can lead to disability, dependency and even suicide. OLEPTROâ“ž¢ (trazodone hydrochloride) extended-release tablets were launched in August of this year as a treatment for MDD in adults. Two...

a9fa77c7e24e5b134d43b25071749344
2010-10-09 07:40:00

"Pink Viagra," an experimental pill claiming to boost a woman's sex drive, has been scrapped by German maker Boehringer Ingelheim after failing to convince US regulators that the pill actually worked. "The decision was not made lightly, considering the advanced stage of development," CEO Andreas Barner told Reuters on Friday. The company had hoped the pill would have been a potential windfall aimed at premenopausal women with a persistent lack of sex drive. The move marked the failure of...

2010-10-08 10:46:00

ABBOTT PARK, Ill., Oct. 8 /PRNewswire/ -- Abbott (NYSE: ABT) will voluntarily withdraw Meridia® (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA). The FDA's request is based primarily on the results of the SCOUT (Sibutramine Cardiovascular OUTcome Trial) study, an approximately 10,000 patient, 6-year study requested by European regulatory authorities as a post-marketing commitment to evaluate cardiovascular safety in...

f9634f5bbce76e8c2605948af469a8e2
2010-10-02 05:20:00

A plant that has been used for hundreds of years by indigenous South Africans for reducing stress, relieving hunger, sedating and elevating moods, has now been approved for study and market, and it could soon be for sale over-the-counter worldwide. The plant, sceletium tortuosum, has great potential and could boost the local economy, researchers studying the plant and its effects told the Associated Press (AP). The American pharmaceutical company working on the project said, however, that...

2010-09-15 16:03:00

ABBOTT PARK, Ill., Sept. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT (Sibutramine Cardiovascular OUTcome Trial) and the weight loss medication sibutramine (sold as Meridia® in the United States). In response to the Advisory Committee's mixed vote, Abbott (NYSE: ABT) issued the following statement: "Today's vote highlights the complexity of this...

2010-08-10 08:00:00

LAVAL, QC, Aug. 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of...

2010-08-10 07:45:00

PRINCETON, N.J., Aug. 10 /PRNewswire/ -- Angelini Labopharm today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, is now commercially available in the United States. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release...

2010-07-09 06:00:00

- More Favourable Payment Terms Provide Additional Financial Flexibility as Company Prepares to Launch OLEPTRO(TM) in the U.S. This Quarter - LAVAL, QC, July 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC) has agreed to amend Labopharm's debt facility agreement such that Hercules has extended both the period of interest-only payments on the loan and the maturity date of the loan. The amended...


Latest Antidepressants Reference Libraries

2012-06-15 03:50:16

Symbol: MUPRU Group: Dicot Family: Fabaceae Duration: Annual Growth Habit: Vine Forb/herb Native Status: L48    N Synonyms:   MUAT2 Mucuna aterrima (Piper & Tracy) Holland   MUDE2 Mucuna deeringiana (Bort) Merr.   STAT3 Stizolobium aterrimum Piper & Tracy   STDE Stizolobium deeringianum Bort   STVE5 Stizolobium velutinum (Hassk.) Piper & Tracy Distribution: Mucunapruriens(L.) DC. var.utilis(Wall. ex Wight) Baker ex Burck...

More Articles (1 articles) »
Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related